LYRA · As filed with the SEC
Lyra Therapeutics balance sheet, by fiscal year
The statement as Lyra Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 15,893,000 | 40,577,000 | 22,353,000 | 32,550,000 |
| Short-term investments | — | 0 | 80,400,000 | 65,344,000 |
| Prepaid expenses and other current assets | 379,000 | 2,448,000 | 2,068,000 | 2,935,000 |
| Total current assets | 16,272,000 | 43,025,000 | 104,821,000 | 100,829,000 |
| Property and equipment, net | 1,051,000 | 1,404,000 | 2,043,000 | 2,243,000 |
| Operating lease right-of-use assets | 16,792,000 | 19,924,000 | 33,233,000 | 2,223,000 |
| Restricted cash | 1,993,000 | 1,993,000 | 1,392,000 | 1,392,000 |
| Other assets | — | 0 | 1,111,000 | 3,281,000 |
| Total assets | 36,108,000 | 66,346,000 | 142,600,000 | 109,968,000 |
| Current liabilities: | ||||
| Accounts payable | 663,000 | 1,179,000 | 3,131,000 | 2,616,000 |
| Accrued expenses and other current liabilities | — | — | 9,374,000 | 9,030,000 |
| Restructuring liability | 3,266,000 | 4,347,000 | — | — |
| Accrued expenses and other current liabilities | 775,000 | 2,586,000 | — | — |
| Operating lease liabilities | 4,818,000 | 4,121,000 | 5,434,000 | 1,549,000 |
| Deferred revenue | — | 398,000 | 1,658,000 | 1,275,000 |
| Total current liabilities | 9,522,000 | 12,631,000 | 19,597,000 | 14,470,000 |
| Operating lease liabilities, net of current portion | 25,441,000 | 30,259,000 | 21,447,000 | 667,000 |
| Deferred revenue, net of current portion | 11,862,000 | 11,862,000 | 12,136,000 | 14,077,000 |
| Total liabilities | 46,825,000 | 54,752,000 | 53,180,000 | 29,214,000 |
| Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2025 and 2024; 1,774,882 and 1,310,308 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 2,000 | 65,000 | 57,000 | 32,000 |
| Additional paid-in capital | 422,990,000 | 416,319,000 | 400,685,000 | 329,387,000 |
| Accumulated other comprehensive income, net of tax | — | 0 | 33,000 | 10,000 |
| Accumulated deficit | (433,709,000) | (404,790,000) | (311,355,000) | (248,675,000) |
| Total stockholders' (deficit) equity | (10,717,000) | 11,594,000 | 89,420,000 | 80,754,000 |
| Total liabilities and stockholders' (deficit) equity | 36,108,000 | 66,346,000 | 142,600,000 | 109,968,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.